Anixa Biosciences Inc
Company Profile
Business description
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Contact
3150 Almaden Expressway
Suite 250
San JoseCA95118
USAT: +1 408 708-9808
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 October 2026
Employees
4
Stocks News & Analysis
stocks
Beaten down real estate share receives legal blow
stocks
OpenAI joins the mega-AI lab IPO race, but timing is uncertain
stocks
What happens if Tesla and SpaceX merge?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,997.00 | 20.00 | 0.22% |
| CAC 40 | 8,200.80 | 38.97 | 0.48% |
| DAX 40 | 24,209.71 | 14.40 | 0.06% |
| Dow JONES (US) | 50,848.75 | 929.97 | 1.86% |
| FTSE 100 | 10,303.88 | 49.07 | 0.48% |
| HKSE | 24,691.96 | 442.67 | 1.83% |
| NASDAQ | 25,809.66 | 640.16 | 2.54% |
| Nikkei 225 | 66,442.95 | 2,225.68 | 3.47% |
| NZX 50 Index | 13,335.16 | 133.00 | 1.01% |
| S&P 500 | 7,394.30 | 127.31 | 1.75% |
| S&P/ASX 200 | 8,795.30 | 21.80 | 0.25% |
| SSE Composite Index | 4,057.88 | 70.87 | 1.78% |